Critical appraisal of IFN-α-based adjuvant therapy in Stage II–III malignant melanoma

References

• Eggermont AMM. The current EORTC Melanoma Co-operative Group adjuvant trial program on malignant melanoma: prognosis versus efficacy, toxicity and costs. Melanoma Res.7\(Suppl. 2), S127-131 (1997).
   Google Scholar
• Morton DL, Eilber FR, Homes EC et al Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases. Aust NZ J. Surg. Clin. Oncol IZ 434a (1978).
   Google Scholar
• Hersey P, Coates A, McCarthy WH. Interim analysis of a randomized trial of immunotherapy with vaccinia melanoma cell lysates [VNICL] following surgical removal of high risk melanoma. Proc. Am. Assoc. Cancer Res. 37,489 (1996) (Abstract).
   Google Scholar
• Wallack MK, Sivanandham M, Balch CM et al. Surgical adjuvant active specific immunotherapy for patients with Stage III melanoma: the final analysis of data from a Phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. Am. Coll Surg 187,69–77 (1998).
   PubMed Web of Science ®Google Scholar
• Sondak V, Liu PY, Kempf RA et al. SWOG-9035: adjuvant therapy of intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine. J. Immunother. 5, 600 (2000) (Abstract).
   Google Scholar
• Bystryn JC, Zeleniuch-Jaquotte A, Oratz R et al Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin. Cancer Res. 7, 1837–1838 (2001).
   PubMed Web of Science ®Google Scholar
• Livingstone PO, Wong GYC, Adluri S et al. Improved survival in Stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. j Clin. Oncol 12, 1036–1044 (1994).
   Google Scholar
• Sosman JA, Unger JM, Liu PY et al. Significant impact of HLA class I alleles on outcome in T3NOMO melanoma patients treated with Melacine (MEL): an allogeneic cell lysate vaccine: prospective analysis of Southwest Oncology Group (SWOG) - 9035. Proc. Am. Soc. Clin. Oncol 20,351 (2001) (Abstract).
   Google Scholar
• Kirkwood JM. Melanoma. In: Biologis Therapy of Cancer' Principles and Practice. DeVita VT Jr, Hellman S, Rosenberg SA (Eds), Phildelphia, PA, USA, 388–411 (1995).
   Google Scholar
• Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-a-mediated downregulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res. 5, 2726–2734 (1995).
   Google Scholar
• Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon a-2b to dacarbazine in the treatment of patients with metastatic melagnant melanoma. J. Clin. Oncol 9, 1403–1408 (1991).
   Google Scholar
• Tomson DB, Adena M, McLeod GRC et al. Interferon-a 2a does not improve response or survival when combined with dacarbazide in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res. 3, 133–138 (1993).
   PubMed Web of Science ®Google Scholar
• Sparano JA, Fisher RI, Sunderland M et al. Randomized Phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon a-2a in patients with advanced melanoma. J. Clin. Oncol 11,1969-1977 (1993).
   Google Scholar
• Bajetta E, Di Leo A, Zampino MG et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon a-2a in the treatment of advanced melanoma. J. Clin. Oncol 12(4), 806–811 (1994).
   Google Scholar
• Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum R. Phase III trial of dacarbazine versus dacarbazide with interferon al2b versus dacarbazide with tamoxifen versus dacarbazide with interferon a2b wtih tamoxifen in patients with metastatic malignant melanoma: an Eastern Co-operative Oncology Study. J. Clin. Oncol 16, 1743–1751 (1998).
   Google Scholar
• Johnston SR, Constenla DO, Moore J et al. Randomized Phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen1 with or without interferon-a (IFN-a) and interleukin (IL-2) in patients with metastatic melanoma. BE J. Cancer 77, 1280–1286 (1998).
   Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine and tamoxifen alone or in combination with interleukin-2 and interferon a-2b. j Clin. Oncol 17, 968–975 (1999).
   Google Scholar
• Dorval T, Negrier S, Chevreau C et al. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-a-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. Cancer 85, 1060–1066 (1999).
   PubMed Web of Science ®Google Scholar
• Eton O, Legha S, Bedikian A et al. Phase III randomized trial of cisplatin, vinblastine and dacarbazine (CVD) plus interleukin-2 (IL2) and interferon-a-2B (INF) versus CVD in patients (pts) with metastatic melanoma. Proc. 36th Ann. Meet. Am Soc. Clin. Oncol 2174 (2000) (Abstract).
   Google Scholar
• Middleton MR, Lorigan P, Owen J et al. A randomized Phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. BE J. Cancer 82, 1158–1162 (2000).
   Web of Science ®Google Scholar
• Young AM, Marsden J, Goodman A, Burton A, Dunn JA. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-a (IFN-a) in metastatic melanoma. Clin. Oncol 13, 458–465 (2001).
   Google Scholar
• Atzpodien J, Neuber K, Kamanabroe D et a/. Combination chemotherapy with or without sc. IL-2 and IFN-a: results of a prospectively randomized trial of the Co-operative Advanced Malignant Melanoma Chemoimmunotherapy group (ACIMM). Br. Cancer 86, 179–184 (2002).
   Google Scholar
• Ridolfi R, Chiarion-Sileni V, Guida M et al. Cisplatin, dacarbazine with or without sc. interleukin-2 and interferon a-2b in advanced melanoma out-patients: results from an Italian multicenter Phase III randomized clinical trial. 1 Clin. Oncol 20, 1600–1607 (2002).
   Google Scholar
• Kirkwood J. Interferon a-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Co-operative Oncology Group Trial EST 1684.1 Clin. Oncol 17, 7–17 (1996).
   Google Scholar
• Grob JJ, Dreno B, de la Salmoniere P et al. Randomized trial of interferon a-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Co-operative Group on Melanoma. Lancet 351, 1905-1910 (1998).
   Google Scholar
• Creagan ET, Dalton RJ, Ahmann DL et al Randomized surgical adjuvant clinical trial or recombinant interferon-a-2a in selected patients with malignant melanoma. J. Clin. Oncol 13, 2776–2783 (1995).
   Google Scholar
• Kirkwood JM, Ibrahim JG, Sondak VK et al High- and low-dose interferon a-2b in high-risk melanoma: first analysis of intergroup trial E1690/59111/C9190.1 Clin. Oncol 18,2444–2459 (2000).
   Google Scholar
• Kirkwood JM, Manola J, Ibrahim JG, Sondak VK, Ernstoff MS. Pooled analysisof four ECOG-Intergroup trials of high- dose interferon a-2b (HDI) in 1916 patients with high-risk resected cutaneous melanoma. Proc. Ann. Soc. Clin. Oncol 20, 1395 (2002) (Abstract).
   Google Scholar
• Cascinelli N, Bufalino R, Morabito A et al Results of adjuvant interferon study in WHO melanoma programme. Lancet 343, 913–914 (1994).
   PubMed Web of Science ®Google Scholar
• Cascinelli N, Belli F, MacKie RN/I, Santinami M, Bufalino R, Morabito A. Effect of long-term adkivant therapy with interferon a-2a in patients with regional node metastases from cutaneous melanoma: a randomized trial. Lancet 358,866–869 (2001).
   Google Scholar
• Cameron DA, Cornbleet MC, MacKie RM et al. Adjuvant interferon-a in high-risk melanoma: The Scottish study. Br. J. Cancer 84,1146–1149 (2001).
   PubMed Web of Science ®Google Scholar
• Pehamberger H, Soyer P, Steiner A et al Adjuvant interferon a-2a treatment in resected primary stage II cutaneous melanoma. J. Clin. Oncol 16, 1425–1429 (1998).
   Google Scholar
• Kleeberg U, Broecker EB, Chartier C et al. EORTC 18871 adjuvant trial in high risk melanoma patients IFN-a vs. IFN-y vs. Iscador vs. Observation. Eur. J. Cancer 35(S4), 264 (1999) (Abstract).
   Google Scholar
• Lens MB, Dawes M. Interferon-a therapy for malignant melanoma: a systematic review of randomized controlled trials. J. Clin. Oncol 20, 1818–1825 (2002).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon-a-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/59512/C509801. Clin. Oncol 19, 2370–2380 (2001).
   Google Scholar
• Hancock BW, Wheatley K, Harrison G, Gore M. Aim High-Adjuvant interferon in melanoma (high risk), a United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) randomized study of observation versus adjuvant low dose extended duration interferon a-2a in high risk resected malignant melanoma. Pmc. Ann. Soc Cita. Oncol. 20, 1393 (2001) (Abstract).
   Google Scholar
• Eggermont AMI\A, Kleeberg UR, Ruiter DJ, Suciu S. The European Organization for research and Treatment of Cancer Melanoma Group trial experience with more than 2000 patients, evaluating adjuvant therapy treatment with low or intermediate doses of Interferon-a-2b. In: American Society of Clinical Oncology: 2001 Educational Book 37th Annual Meeting. Perry MC (Ed.), Alexandria, VA, USA, 88–93 (2001).
   Google Scholar
• Eggermont AMM, Gore M. European approach to adjuvant treatment of intermediate and high-risk malignant melanoma. Semin. Oncol 29, 382–388 (2002).
   PubMed Web of Science ®Google Scholar
• Groenewegen G, Osanto S, van der Rhee HJ, Punt CJA. Interferon as an adjuvant treatment for melanoma; registered but not indicated. Ned Tijdschr Geneesk, 144, 2160–2161 (2000) (Abstract in English).
   Google Scholar
• Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P Mood and cognitive side effects of interferon-a therapy. Semin. Oncol 25(1 Suppl. 1), 39–47 (1998).
   Google Scholar
• McClay ER Adjuvant therapy for patients with high-risk malignant melanoma. Semin. Oncol. 29, 389–399 (2002).
   Google Scholar
• Wheatley K, Hancock B, Gore M, Suciu S, Eggermont AMM. Interferon-a as adjuvant therapy for melanoma: a meta-analysis of the randomized trials. Proc. Ann. Soc. Cl/n. Oncol 20, 1394 (2001) (Abstract).
   Google Scholar
• Eggermont AMM. Role of interferon-a in malignant melanoma remains to be determined. Eur J. Cancer 37, 2147–2153 (2001).
   PubMed Web of Science ®Google Scholar